Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Imatinib-induced changes in the expression profile of microRNA in the plasma and heart of mice-A comparison with doxorubicin

B. Hanousková, M. Skála, V. Brynychová, T. Zárybnický, V. Skarková, P. Kazimírová, A. Vernerová, P. Souček, L. Skálová, R. Pudil, P. Matoušková,

. 2019 ; 115 (-) : 108883. [pub] 20190417

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006441

Grantová podpora
NV17-28470A MZ0 CEP - Centrální evidence projektů

Cardiotoxicity is a serious adverse reaction to cancer chemotherapy and may lead to critical heart damage. Imatinib mesylate (IMB), a selective tyrosine kinase inhibitor, is sometimes accompanied by severe cardiovascular complications. To minimize risk, early biomarkers of such complications are of utmost importance. At the present time, microRNAs (miRNAs) are intensively studied as potential biomarkers of many pathological processes. Many miRNAs appear to be specific in some tissues, including the heart. In the present study we have explored the potential of specific miRNAs to be early markers of IMB-induced cardiotoxicity. Doxorubicin (DOX), an anthracycline with well-known cardiotoxicity, was used for comparison. NMRI mice were treated with IMB or DOX for nine days in doses corresponding to the highest recommended doses in oncological patients, following which plasmatic levels of miRNAs were analyzed in miRNA microarrays and selected cardio-specific miRNAs were quantified using qPCR. The plasmatic level of miR-1a, miR-133a, miR-133b, miR-339, miR-7058, miR-6236 and miR-6240 were the most different between the IMB-treated and control mice. Interestingly, most of the miRNAs affected by DOX were also affected by IMB showing the same trends. Concerning selected microRNAs in the hearts of individual mice, only miR-34a was significantly increased after DOX treatment, and only miR-205 was significantly decreased after IMB and DOX treatment. However, no changes in any miRNA expression correlated with the level of troponin T, a classical marker of heart injury.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006441
003      
CZ-PrNML
005      
20220606083051.0
007      
ta
008      
200511s2019 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2019.108883 $2 doi
035    __
$a (PubMed)31004989
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Hanousková, Barbora $u Faculty of Pharmacy, Charles University, Heyrovského 1203, Hradec Králové, Czech Republic.
245    10
$a Imatinib-induced changes in the expression profile of microRNA in the plasma and heart of mice-A comparison with doxorubicin / $c B. Hanousková, M. Skála, V. Brynychová, T. Zárybnický, V. Skarková, P. Kazimírová, A. Vernerová, P. Souček, L. Skálová, R. Pudil, P. Matoušková,
520    9_
$a Cardiotoxicity is a serious adverse reaction to cancer chemotherapy and may lead to critical heart damage. Imatinib mesylate (IMB), a selective tyrosine kinase inhibitor, is sometimes accompanied by severe cardiovascular complications. To minimize risk, early biomarkers of such complications are of utmost importance. At the present time, microRNAs (miRNAs) are intensively studied as potential biomarkers of many pathological processes. Many miRNAs appear to be specific in some tissues, including the heart. In the present study we have explored the potential of specific miRNAs to be early markers of IMB-induced cardiotoxicity. Doxorubicin (DOX), an anthracycline with well-known cardiotoxicity, was used for comparison. NMRI mice were treated with IMB or DOX for nine days in doses corresponding to the highest recommended doses in oncological patients, following which plasmatic levels of miRNAs were analyzed in miRNA microarrays and selected cardio-specific miRNAs were quantified using qPCR. The plasmatic level of miR-1a, miR-133a, miR-133b, miR-339, miR-7058, miR-6236 and miR-6240 were the most different between the IMB-treated and control mice. Interestingly, most of the miRNAs affected by DOX were also affected by IMB showing the same trends. Concerning selected microRNAs in the hearts of individual mice, only miR-34a was significantly increased after DOX treatment, and only miR-205 was significantly decreased after IMB and DOX treatment. However, no changes in any miRNA expression correlated with the level of troponin T, a classical marker of heart injury.
650    _2
$a zvířata $7 D000818
650    _2
$a doxorubicin $x toxicita $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese $x účinky léků $7 D005786
650    _2
$a srdce $x účinky léků $7 D006321
650    _2
$a imatinib mesylát $x farmakologie $7 D000068877
650    _2
$a myši $7 D051379
650    _2
$a mikro RNA $x krev $x genetika $x metabolismus $7 D035683
650    _2
$a transkriptom $x účinky léků $7 D059467
650    _2
$a troponin T $x krev $x genetika $x metabolismus $7 D020107
655    _2
$a časopisecké články $7 D016428
700    1_
$a Skála, Mikuláš $u Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Králové, Czech Republic; Department of Pulmology, University Hospital in Hradec Králové, Hradec Králové, Czech Republic. $7 xx0273596
700    1_
$a Brynychová, Veronika $u The National Institute of Public Health, Šrobárova 48, Praha 10, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, Plzeň, Czech Republic.
700    1_
$a Zárybnický, Tomáš $u Faculty of Pharmacy, Charles University, Heyrovského 1203, Hradec Králové, Czech Republic.
700    1_
$a Skarková, Veronika $u Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Králové, Czech Republic.
700    1_
$a Kazimírová, Petra $u Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Králové, Czech Republic.
700    1_
$a Vernerová, Andrea $u Faculty of Pharmacy, Charles University, Heyrovského 1203, Hradec Králové, Czech Republic.
700    1_
$a Souček, Pavel $u The National Institute of Public Health, Šrobárova 48, Praha 10, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, Plzeň, Czech Republic.
700    1_
$a Skálová, Lenka $u Faculty of Pharmacy, Charles University, Heyrovského 1203, Hradec Králové, Czech Republic.
700    1_
$a Pudil, Radek $u Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Králové, Czech Republic.
700    1_
$a Matoušková, Petra $u Faculty of Pharmacy, Charles University, Heyrovského 1203, Hradec Králové, Czech Republic. Electronic address: matousp7@faf.cuni.cz.
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 115, č. - (2019), s. 108883
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31004989 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20220606083049 $b ABA008
999    __
$a ok $b bmc $g 1525299 $s 1096497
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 115 $c - $d 108883 $e 20190417 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
GRA    __
$a NV17-28470A $p MZ0
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace